Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 20;31(1):24-41.
doi: 10.3390/curroncol31010002.

Management of Uveal Melanoma: Updated Cancer Care Alberta Clinical Practice Guideline

Ezekiel Weis  1   2 , Brae Surgeoner  3 , Thomas G Salopek  4 , Tina Cheng  5 , Martin Hyrcza  6 , Xanthoula Kostaras  3 , Matthew Larocque  7 , Greg McKinnon  8 , John McWhae  9 , Geetha Menon  7 , Jose Monzon  5 , Albert D Murtha  10 , John Walker  11 , Claire Temple-Oberle  8
Affiliations
Review

Management of Uveal Melanoma: Updated Cancer Care Alberta Clinical Practice Guideline

Ezekiel Weis et al. Curr Oncol. .

Abstract

Objective: The purpose of this guideline update is to reassess and update recommendations in the prior guideline from 2016 on the appropriate management of patients with uveal melanoma.

Methods: In 2021, a multidisciplinary working group from the Provincial Cutaneous Tumour Team, Cancer Care Alberta, Alberta Health Services was convened to update the guideline. A comprehensive review of new research evidence in PubMed as well as new clinical practice guidelines from prominent oncology groups informed the update. An enhancement in methodology included adding levels of evidence and strength of recommendations. The updated guideline was circulated to all members of the Provincial Cutaneous Tumour Team for review and endorsement.

Results: New and modified recommendations address provider training requirements, diagnostic imaging for the detection of metastases, neo-adjuvant pre-enucleation radiotherapy, intravitreal anti-vascular endothelial growth factor agents for radiation retinopathy, genetic prognostic testing, surveillance following definitive local therapy, and systemic therapy for patients with metastatic uveal melanoma.

Discussion: The recommendations represent evidence-based standards of care agreed to by a large multidisciplinary group of healthcare professionals.

Keywords: choroidal melanoma; iris melanoma; melanoma; ocular melanoma; ophthalmology; practice guidelines; uveal melanoma.

PubMed Disclaimer

Conflict of interest statement

E.W. participates on the Castle Biosciences, Inc. Advisory Board (no financial renumeration or interest) outside the submitted work. J.W. participated in Immunocore’s phase II tebentafusp trial (ClinicalTrials.gov number, NCT03070392).

References

    1. Singh A.D., Topham A. Survival rates with uveal melanoma in the United States: 1973–1997. Ophthalmology. 2003;110:962–965. doi: 10.1016/S0161-6420(03)00077-0. - DOI - PubMed
    1. Egan K.M., Seddon J.M., Glynn R.J., Gragoudas E.S., Albert D.M. Epidemiologic aspects of uveal melanoma. Surv. Ophthalmol. 1988;32:239–251. doi: 10.1016/0039-6257(88)90173-7. - DOI - PubMed
    1. Gallagher R.P., Elwood J.M., Rootman J., Spinelli J.J., Hill G.B., Threlfall W.J., Birdsell J.M. Risk factors for ocular melanoma: Western Canada Melanoma Study. J. Natl. Cancer Inst. 1985;74:775–778. - PubMed
    1. Weis E., Shah C.P., Lajous M., Shields J.A., Shields C.L. The association of cutaneous and iris nevi with uveal melanoma: A meta-analysis. Ophthalmology. 2009;116:536–543.e532. doi: 10.1016/j.ophtha.2008.10.008. - DOI - PubMed
    1. Weis E., Shah C.P., Lajous M., Shields J.A., Shields C.L. The association between host susceptibility factors and uveal melanoma: A meta-analysis. Arch. Ophthalmol. 2006;124:54–60. doi: 10.1001/archopht.124.1.54. - DOI - PubMed